(
EMAILWIRE.COM, January 29, 2018 ) The
Latin America Multiple Myeloma Therapeutics Market was worth $0.94 billion in 2016 and estimated to be growing at a CAGR of 5.33%, to reach $1.21 billion by 2021.
Multiple myeloma is a specifically fatal but less common type of blood cancer effects in eventual patient deteriorations even after therapy and is universally considered as lethal. Incidence of multiple myeloma is increasing with each passing year. The disease mostly affects the aged, assumed the average age of disease start at around 70 years.
Browse for Market Segmentation and TOC @
https://marketdataforecast.com/market-reports/latin-america-multiple-myeloma-therapeutics-market-862/Expanding indications of existing drugs, emergence of new and promising drugs, increasing incidence of multiple myeloma and increasing use of drugs already on the market are fuelling growth of the market. Moreover, growth is being driven by the drive to novel drugs in search of higher effectiveness and safety and increasing use of these high prices medicines for the treatment of the condition. Stringent regulation is the key factor hindering the multiple myeloma therapeutics market.
Get Free Sample Report @
https://marketdataforecast.com/market-reports/latin-america-multiple-myeloma-therapeutics-market-862/request-sampleThe Latin America Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @
https://marketdataforecast.com/market-reports/latin-america-multiple-myeloma-therapeutics-market-862/inquireBased on geography the market is analysed under various regions namely, Brazil, Argentina and Mexico. Mexico is dominating the multiple myeloma therapeutics market in the Latin America region and is expected to continue its dominance over the forecast period.
Buy now @
https://marketdataforecast.com/cart/buy-now/latin-america-multiple-myeloma-therapeutics-market-862/Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit,
www.marketdataforecast.com.
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.comSource:
EmailWire.Com 
